IgG4-related disease is a rare and serious autoimmune disease that affects one or more organs in the body. In an autoimmune disease, the immune system (the body’s natural defenses) attacks the body’s normal cells and organs.
There is currently no approved medication for IgG4-related disease. Standard treatment is to lower inflammation with steroid treatment, such as prednisone
Taking steroids for long periods of time can lead to side effects and complications, especially for older people. This is why doctors and researchers are looking for new ways to treat IgG4-related disease.
Research has shown that B cells (a type of white blood cell) play an important role in IgG4-related disease. An experimental medicine called obexelimab [ah-bex-EL-ih-mab] has been developed to target the harmful actions of B cells in IgG4-related disease. This is a new approach to treating IgG4-related disease.
Your immune (defense) system normally makes antibodies to fight bacteria and viruses. Scientists can make antibodies in a laboratory. When mass produced for medical use, such antibodies are called monoclonal antibodies.
Obexelimab is a monoclonal antibody being studied as a possible treatment option for IgG4-related disease. Obexelimab has been given to healthy volunteers and patients with immune-related diseases in other studies. In the INDIGO study, doctors and researchers want to see if obexelimab can help reduce or even prevent flares caused by IgG4-related disease.